Clinical Pearls for the Treatment of AD
Expert dermatologists share clinical pearls for providers treating patients with AD, and discuss the future of AD treatment.
Read More
Access to JAK Inhibitors in AD
Lisa Swanson, MD, PhD, highlights dermatology biologics coordinators as a resource for getting better access to JAK inhibitors.
Utilizing JAK Inhibitors in Clinical Practice
Dermatology experts discuss the use of JAK inhibitors in clinical practice, highlighting their own experiences and use of JAKs alongside corticosteroids.
Treatment Selection of JAK Inhibitors for the Management of AD
Expert dermatologists speak on shared-decision making between the patient and the provider when it comes to selecting the right therapy for AD.
Contraindications for Use of JAK Inhibitors in AD
Peter Lio, MD, reviews the contraindications of JAK inhibitors in AD and approaches for monitoring patients who are prescribed a JAK inhibitor.
Boxed Warnings for JAK Inhibitors in AD
Alexandra Golant, MD, comments on the boxed warnings on all currently approved JAK inhibitors, as well as the commonly used treatments in dermatology that have boxed warnings.
Safety of JAK Inhibitors Approved for AD Treatment
Expert dermatologists review the safety data of the current JAK inhibitors approved for AD, highlighting adverse events and long-term safety data.
Indications and Efficacy of JAK Inhibitors for AD
Lisa Swanson, MD, PhD, reviews the indications for ruxolitinib, abrocitinib, and upadacitinib, as well as the clinical trial data on efficacy of these JAK inhibitors when treating AD.
Differentiating JAK Inhibitors From Other Therapies in AD
Expert dermatologists discuss the factors that differentiate JAK inhibitors from other AD therapies, highlighting itch scores as they relate to quality of life.
Targeting the JAK-STAT Pathway in AD
Alexandra Golant, MD; Christopher Bunick, MD, PhD; and Peter Lio, MD, comment on how targeting the JAK-STAT (signal transducer and activator of transcription) pathway with JAK inhibitors plays a role in managing AD.
Intro to Janus Kinase (JAK) Inhibitors for Treatment of Atopic Dermatitis (AD)
Peter Lio, MD, and Lisa Swanson, MD, PhD, provide an overview of Janus Kinase (JAK) inhibitors, their pathophysiology, and their mechanism of action in the treatment of atopic dermatitis (AD).
Pearls for Atopic Dermatitis Management
Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.
Patient Adherence in Atopic Dermatitis
Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.
Use of Tralokinumab in Atopic Dermatitis
Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.
Impact of Dupilumab on Quality of Life for Atopic Dermatitis Patients
Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.
Efficacy and Reported Outcomes With JAK Inhibitors in Atopic Dermatitis
Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.
Ideal Candidates for Ruxolitinib Treatment of Atopic Dermatitis
Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.
Safety Profile of Topical Ruxolitinib in Atopic Dermatitis
Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.
Clinical Trials of Topical Ruxolitinib in Atopic Dermatitis
Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.
Overview of JAK Inhibitors in Atopic Dermatitis
Peter A. Lio, MD, provides an overview of emerging JAK inhibitors in the treatment of atopic dermatitis.
Assessing Severity of Atopic Dermatitis
Experts in dermatology consider the use of the Atopic Dermatitis Control Tool and other tools to assess severity of atopic dermatitis.
Treatment Approach to Atopic Dermatitis
Aaron S. Farberg, MD, discusses how new therapies have impacted his approach to treatment of atopic dermatitis.
Traditional Steroids vs Emerging Therapies in Atopic Dermatitis
Alexandra Golant, MD, comments on the adverse events of systemic therapies and how emerging nonsteroidal agents have a better safety profile in atopic dermatitis.
Treatment Landscape in Atopic Dermatitis
Matthew Zirwas, MD, highlights therapies that are available for the treatment of atopic dermatitis, including corticosteroids, calcineurin inhibitors and JAK inhibitors.
The Impact of Atopic Dermatitis on Quality of Life
Expert dermatologists review the impact of atopic dermatitis on quality of life for both the patient and their families.
An Overview of Atopic Dermatitis (AD)
Peter A. Lio, MD, provides an overview of the pathophysiology of atopic dermatitis (AD) and the comorbidities often associated with it.
Future Directions for Atopic Dermatitis Management
Raj J. Chovatiya, MD, PhD; Alexandra K. Golant, MD; Eric Simpson, MD, MCR; and Linda Stein Gold, MD, share clinical pearls and discuss the future treatment landscape for atopic dermatitis.
Patient Challenges With Available Therapies for Atopic Dermatitis
Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, discuss challenges adolescent and adult patients face with current oral and topical therapies and optimizing disease management.
JAK Inhibitors in Clinical Practice for Atopic Dermatitis Treatment
Experts in the management of atopic dermatitis assess the use of JAK inhibitors in clinical practice and considerations for treatment selection for patients with atopic dermatitis.
Using Topical Versus Oral JAK Inhibitors in Atopic Dermatitis
Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, share their approach to prescribing decisions for oral and topical JAK inhibitors for patients with atopic dermatitis.